Ann: FDA approves Daybue - the first treatment for Rett syndrome, page-74

I’m doubtful that Acadia would seek to recoup costs for the development of trofinetide before Neuren would receive any payments. IMO the sum of net sales is minus the direct costs of sales, distribution, administration and manufacturing. From the first sale of trofinetide Neuren will be earning.

PS: It’s long been my assumption that the price of trofinetide will land around the $150k mark. But looking at the payments table, to reach $1 billion in sales would require ~6600 patients at $150k. Not out of reach, but that kind of penetration would be extraordinary. I’m now leaning towards the price being higher, perhaps $200-250k. I noted the Mizhuo analyst pricing the drug at potentially $400k. Personally, I feel $400k would be putting the treatment out of reach for an unacceptable number of families, by the same token to achieve $1 billion in sales would require the price to be somewhat higher than $150k. The sweet spot is hopefully somewhere in between.